151751-Najiba-Chargi

254 CHAPTER 13 42. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol . 2010;21(8):1594- 1598. doi:10.1093/annonc/mdp605 43. Chemama S, Bayar MA, Lanoy E, et al. Sar - copenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreduc - tive Surgery with Hyperthermic Intraperito - neal Chemotherapy for Peritoneal Carcino- matosis from Colorectal Cancer. Ann Surg Oncol . 2016;23(12):3891-3898. doi:10.1245/ s10434-016-5360-7 44. Cushen SJ, Power DG, Murphy KP, et al. Impact of body composition parame- ters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN . 2016;13:e39-e45. doi:10.1016/j. clnesp.2016.04.001 45. Cushen SJ, Power DG, Teo MY, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol Cancer Clin Trials . 2017;40(1):47- 52. doi:10.1097/COC.0000000000000061 46. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sar- copenic obesity in patients with solid tu- mours of the respiratory and gastrointesti- nal tracts: a population-based study. Lancet Oncol . 2008;9(7):629-635. doi:10.1016/ S1470-2045(08)70153-0 47. Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: Skel- etal muscle depletion is a powerful prog- nostic factor, independent of body mass index. J Clin Oncol . 2013;31(12):1539-1547. doi:10.1200/JCO.2012.45.2722 48. Fujiwara N, Nakagawa H, Kudo Y, et al. Sar - copenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol . 2015;63(1):131-140. doi:10.1016/j. jhep.2015.02.031 49. Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol . 2018;4(6):798- 804. doi:10.1001/jamaoncol.2018.0137 50. Huiskamp LFJ, Chargi N, Devriese LA, de Jong PA, de Bree R. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiothera- py. Eur Arch Otorhinolaryngol . April 2020. doi:10.1007/s00405-020-05972-2 51. Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol . 2018;4(6):798- 804. doi:10.1001/jamaoncol.2018.0137 52. Kurk S, Peeters P, Stellato R, et al. Skel - etal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle . 2019;10(4):803-813. doi:10.1002/jcsm.12436 53. De Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A. Population pharma - cokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol . 2004;54(2):105-112. doi:10.1007/s00280- 004-0790-5 54. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinet- ics in the absence and presence of pacli- taxel. Clin Cancer Res . 1996;2(3). 55. Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. In: Profiles of Drug Substances, Excipients and Related Methodology . Vol 44. Academic Press Inc.; 2019:239-266. doi:10.1016/bs.podrm.2018.11.003 56. CHMP. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS .